Kavita Mardi
Kavita Mardi
Mohamed Ahmed Ali,Yasar A Ahmed,Abubaker Ibrahim
Mohamed Ahmed Ali
Multiple myeloma is a malignant plasma cell disorder that accounts for approximately 10% of all hematological cancers. It is characterized by accumulation of clonal plasma cells, predominantly in the bone marrow. The prevalence of type 2 di...
Itrat Mehdi,Bassim Jaffar Al-Bahrani
Itrat Mehdi
Oncology patient care is an ever evolving field both as a science and a clinical art. We evaluate, diagnose, and treat cancer patients daily. We break the bad and the good news to them. We are the hope on which their life and dreams hang on...
Satya Bhusan Senapati,Sudhansu Sekhar Mishra,Manmath Kumar Dhir et al.
Satya Bhusan Senapati et al.
Pseudo Chediak Higashi-like inclusions in myeloblasts in AML-M2 [0.03%]
急性髓系白血病M2中的粒细胞原始细胞假Chediak-Higashi小体样包涵体
Sunita Sharma,Shivani Kushwaha,Atul Goel et al.
Sunita Sharma et al.
Angelina's choice [0.03%]
安吉丽娜的选择
Nishu Singh Goel
Nishu Singh Goel
This is an opinion piece on how a celebrity's personal choice to undergo prophylactic mastectomy on discovery of an aberrant gene, when publicly promoted, carries in itself the power to influence and impact healthcare trends and decisions. ...
Syed Md Akram Hussain
Syed Md Akram Hussain
Bangladesh, at 142 million people, is the ninth most populous country in the world. There are 13 to 15 lakh cancer patients in Bangladesh, with about two lakh patients newly diagnosed with cancer each year. As an overview, lung cancer and m...
Confusion worse confounded [0.03%]
混淆视听愈发糟糕
Vanita Noronha,Amit Joshi,Kumar Prabhash
Vanita Noronha
Prasad Narayanan
Prasad Narayanan
The clinical sequelae from bone metastases, termed skeletal-related events (SREs), are among the most frequent and debilitating complications in patients with advanced cancer. Bone metastases are characterized by pathologically increased os...
Challenges in optimizing chemoradiation in locally advanced non small-cell lung cancers in India [0.03%]
印度局部晚期非小细胞肺癌化学放射治疗优化的挑战
Sushma Agrawal
Sushma Agrawal
Data supporting use of concurrent chemoradiation in locally advanced lung cancers comes from clinical trials from developed countries. Applicability and outcomes of such schedules in developing countries is not widely reported. There are va...